Ironwood Pharmaceuticals, Inc.

Microbia, Inc.

Whitehead Institute for Biomedical Research

Forest Laboratories Holdings Limited

Ironwood Pharmaceutical, Inc.

Brian Cali

Mark G Currie

Angelika Fretzen

Daniel P Zimmer

Amir Sherman

Peter Hecht

John Jeffrey Talley

G Todd Milne

Marco Kessler

Craig N Zimmerman

Barbara B Chen

Mahendra G Dedhiya

Timothy Claude Barden

Kevin T Madden

Steffen Rupp

Yun Mo

Yueh-Tyng Chien

Eric F Summers

Sofie Salama

Eric Summers

Cora Ann Styles

Laura Robertson

Radclyffe Roberts

Hiten Madhani

Hsiu-Jung Lo

Todd Milne

Thea Norman

Joshua Trueheart

Jeffrey Cruz Silva

Kevin Sprott

Gerald R Fink

Ara Mermerian

John C Royer

James Philip Pearson

Douglas A Holtzman

Charles Kim

Jane Yang

Mary Maxon

Peter Scott Yorgey

Wayne Schairer

Wilmin Bartolini

Josh Trueheart

Jing Jing Yang

Robert Busby

Doug Holtzman

Jeff Silva

Lixin Zhang

Regina Lundigran

Eduardo Martinez

Gerald L Fink

Stephen Antonelli

Regina Lundrigan-Soucy

Jing-Jing Yang

Etchell Cordero

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

Stable formulations of linaclotide

The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including inflammatory bowel disease (IBD), diverticulitis, colon cancer, an inflammatory disorder, obesity, congestive heart failure, benign prostatic hyperplasia (BPH), pain, salt retention or fluid retention.

Treatments for gastrointestinal disorders

The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.

Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.

Indoles that have activity as inhibitors of FAAH are described as are indoles and indole derivatives that have activity as inhibitors of DAO.

Useful indole compounds

4-Biarylyl-1-phenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of the general formula in which represents an aryl or heteroaryl residue; Ar represents an aryl residue; U is a two to six atom chain; and the R's represent substituents.

4-Biarylyl-1-phenylazetidin-2-ones

The invention relates to the therapeutic or prophylactic treatment of fungal infections. The invention provides new methods for therapeutically or prophylactically treating fungal infections using sub-lethal concentrations of an anti-invasin compound. The methods according to the invention have fewer toxicology problems than existing methods, and thus can be used prophylactically, as well as for early treatment for high risk patients without a firm diagnosis. The methods according to the invention can also be used to treat an established fungal infection. The invention further provides novel genes that regulate fungal hyphal growth.

Use of sublethal concentrations of anti-invasin compounds to therapeutically or prophylactically treat fungal infections

Modulators of the CRTH2 receptor and their use in the treatment of various disorders, including asthma are described.

Modulators of CRTH2 activity

The invention relates to the production of secondary metabolites by fungi. More particularly, the invention relates to improvement of production of commercially important secondary metabolites by fungi. The invention provides methods for improving secondary metabolite production in a fungus, comprising modulating the expression of a gene involved in regulation of secondary metabolite production.

Methods for improving secondary metabolite production in fungi

The invention relates to regulators of fungal gene expression and their use in commercial and medical applications. More particularly, the invention relates to regulators of fungal genes involved in production of enzymes, secondary metabolites and other useful products, as well as to regulators of genes involved in fungal invasion. The invention provides novel regulators of fungal gene expression, and methods for using regulator genes in commercial and medical applications.

Isolated nucleic acid molecule encoding a regulator of fungal gene expression

Disclosed herein are methods for regulating fungal gene expression, and reagents for carrying out those methods.

Regulation of fungal gene expression

Growing community of inventors

Arlington, MA, United States of America

Brian Cali